A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma

NCT00647101 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Open-Angle
Ocular Hypertension

Interventions

DRUG: Latanoprost

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.